LTRN
Lantern Pharma Inc.
Key Financials
Operating Income
$-17978494
↑ 19.1%
Total Liabilities
$4.5M
↑ 2.7%
Net Income
$-17119438
↑ 17.6%
Total Assets
$11.0M
↓ 56.8%
Cash & Equivalents
$4.4M
↓ 41.1%
EPS (Diluted)
$-1.57
↑ 18.7%
Shareholders' Equity
$6.5M
↓ 69.2%
Operating Cash Flow
$-15676980.00
↑ 12.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 8/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/4/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
| SCHEDULE 13G/A | 7/23/2026 | View on SEC |
| EFFECT | 6/18/2026 | View on SEC |
| S-1 | 6/12/2026 | View on SEC |
| 8-K | 6/2/2026 | View on SEC |
| D | 5/21/2026 | View on SEC |
| SCHEDULE 13D/A | 5/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LTRN |
| Company Name | Lantern Pharma Inc. |
| CIK | 1763950 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | TX |
| Phone | 972-277-1136 |